{{Rsnum
|rsid=2716610
|Gene=LPIN1
|Chromosome=2
|position=11819256
|Orientation=minus
|GMAF=0.2544
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=LPIN1
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 0.0 | 25.4 | 74.6
| HCB | 6.7 | 35.6 | 57.8
| JPT | 0.0 | 22.7 | 77.3
| YRI | 33.9 | 48.4 | 17.7
| ASW | 0.0 | 0.0 | 0.0
| CHB | 6.7 | 35.6 | 57.8
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}{{PMID Auto
|PMID=21263402
|Title=Association of PPARG and LPIN1 gene polymorphisms with metabolic syndrome and type 2 diabetes
}}{{PMID|18591397|OA=1
}} Evaluating the role of LPIN1 variation in insulin resistance, body weight, and human lipodystrophy in U.K. Populations.

{{PMID|18693052}} LPIN1 genetic variation is associated with rosiglitazone response in type 2 diabetic patients.

{{PMID|18974842|OA=1
}} Gender differences in genetic risk profiles for cardiovascular disease.

{{PMID|21448847}} Lipin 1 gene polymorphisms in polycystic ovary syndrome.